Business Context and Reporting Period
This Form 8-K was filed by NewAmsterdam Pharma Company N.V. on September 21, 2026. The report details a significant regulatory milestone regarding the Company's lead asset, obicetrapib, in partnership with Menarini Group.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. However, it outlines the financial structure of the licensing agreement with Menarini Group:
- Royalties: Tiered double-digit percentages ranging from low double-digits to mid-twenties on net sales in the Menarini Territory.
- Milestone Payments: Up to an additional €833 million upon achievement of various clinical, regulatory, and commercial milestones.
- Immediate Trigger: Milestone payments in the mid-teens of millions of euros were triggered by the European Commission's marketing authorizations.
Material Changes
The primary material change is the first worldwide regulatory approval of obicetrapib. On September 21, 2026, the European Commission (EC) granted marketing authorization for:
- Ubeslo®: Obicetrapib 10 mg monotherapy.
- Evlarco®: Fixed-dose combination of 10 mg obicetrapib plus 10 mg ezetimibe.
These authorizations apply to patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia across all EU Member States, Iceland, Liechtenstein, and Norway.
Outlook, Risks, and Contingencies
Management Commentary and Obligations: The authorizations require customary post-approval safety monitoring, pharmacovigilance, and risk-minimization measures. Crucially, the EC has mandated a post-authorization efficacy study. The Company must submit final results from the PREVAIL cardiovascular outcomes trial, a placebo-controlled, double-blind, randomized trial evaluating obicetrapib as an adjunct to maximally tolerated lipid-lowering therapies.
Commercialization: Menarini Group holds exclusive commercialization rights in Europe and is responsible for regulatory interactions and commercial activities in the region.
Investor Verification Checklist
- Verify the exact amount of the immediate milestone payment triggered by the EC authorization (stated as "mid-teens of millions of euros").
- Confirm the timeline for the submission of PREVAIL trial results required by the EC.
- Review the specific tiered royalty percentages applicable to net sales in the Menarini Territory.
- Monitor Menarini Group's commercialization launch strategy for Ubeslo® and Evlarco® in the EU.